Search results
Results from the WOW.Com Content Network
DOTA-TATE can be reacted with the radionuclides gallium-68 (T 1/2 = 68 min), lutetium-177 (T 1/2 = 6.65 d) and copper-64 (T 1/2 = 12.7 h) to form radiopharmaceuticals for positron emission tomography (PET) imaging or radionuclide therapy. 177 Lu DOTA-TATE therapy is a form of peptide receptor radionuclide therapy (PRRT) which targets ...
As well as diagnosis and staging of NETs, 68 Ga DOTA conjugated peptide imaging may be used for planning and dosimetry in preparation for lutetium-177 or yttrium-90 DOTA therapy. [35] [36] In June 2016, Netspot (kit for the preparation of gallium Ga-68 dotatate injection) was approved for medical use in the United States. [37] [38]
Gallium (68 Ga) gozetotide or Gallium (68 Ga) PSMA-11 sold under the brand name Illuccix among others, is a radiopharmaceutical made of 68 Ga conjugated to prostate-specific membrane antigen (PSMA) targeting ligand, Glu-Urea-Lys(Ahx)-HBED-CC, used for imaging prostate cancer by positron emission tomography (PET). [11]
[68 Ga] DOTA-pseudopeptides [68 Ga] DOTA-TATE [68 Ga] PSMA [68 Ga] CXCR4; solid and hematologic cancers; Infectious diseases. 18 F] Fluorodeoxysorbitol (FDS) Further ...
The use of metal-free columns allows direct labeling of 68 Ga without prepurification, hence making production of gallium-68-radiolabeled compounds more convenient. The mobile phase is a solvent able to elute (wash out) gallium-68 (III) (68 Ga 3+) after it has been produced by electron capture decay from the immobilized (absorbed) germanium-68.
Among them, the most commercially important radioisotopes are gallium-67 and gallium-68. Gallium-67 (half-life 3.3 days) is a gamma-emitting isotope (the gamma ray emitted immediately after electron capture) used in standard nuclear medical imaging, in procedures usually referred to as gallium scans. It is usually used as the free ion, Ga 3 ...
Clinical trial number NCT04186819 for "Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)" at ClinicalTrials.gov
Lutetium (177 Lu) oxodotreotide or 177 Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors . [ 5 ]